Amantadine in unvaccinated patients with early, mild to moderate COVID-19: A randomized, placebo-controlled, double-blind trial.

ABSTRACT:

Background and purpose

Adamantanes were listed as an interesting option as an early intervention against COVID-19. We aimed to evaluate the effectiveness of amantadine in preventing the progression of COVID-19 and its neurological sequelae.

Methods

Unvaccinated patients with confirmed SARS-CoV-2 infection within 5 days were enrolled. Subjects were randomized (50:50) to amantadine (AMD; 100 mg twice daily) or placebo (PLB) for 14 days. The Ordinal Scale for Clinical Improvement of the World Health Organization (OSCI-WHO) was the primary measure. Secondary endpoints included assessment for fatigue; depression, disorders of smell and taste, and sleepiness on Days 1 and 15.

Results

We enrolled 99 patients (49 AMD and 50 PLB). Disease progression (OSCI-WHO = 4) was observe

SUBMITTER: Rejdak K 

PROVIDER: S-EPMC11235826 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature